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Evidence-based thresholds for risk stratification based on pulse pressure (PP) are currently
unavailable. To derive outcome-driven thresholds for the 24–h ambulatory PP, we analyzed 9938
people randomly recruited from 11 populations (47.3% women). After age stratification (<60 vs.
≥60 years) and using average risk as reference, we computed multivariable-adjusted hazard ratios
(HRs) to assess risk by tenths of the PP distribution or risk associated with stepwise increasing (+1
mm Hg) PP levels. All adjustments included mean arterial pressure. Among 6028 younger
participants (68,853 person-years), the risk of cardiovascular (HR, 1.58; P=0.011) or cardiac (HR,
1.52; P=0.056) events increased only in the top PP tenth (mean, 60.6 mm Hg). Using stepwise
increasing PP levels, the lower boundary of the 95% confidence interval of the successive
thresholds did not cross unity. Among 3910 older participants (39,923 person-years), risk
increased (P≤0.028) in the top PP tenth (mean, 76.1 mm Hg). HRs were 1.30 and 1.62 for total
and cardiovascular mortality, and 1.52, 1.69 and 1.40 for all cardiovascular, cardiac and
cerebrovascular events. The lower boundary of the 95% confidence interval of the HRs associated
with stepwise increasing PP levels crossed unity at 64 mm Hg. While accounting for all
covariables, the top tenth of PP contributed less than 0.3% (generalized R2 statistic) to the overall
risk among elderly. Thus, in randomly recruited people, ambulatory PP does not add to risk
stratification below age 60; in the elderly, PP is a weak risk factor with levels below 64 mm Hg
probably being innocuous.

Keywords
ambulatory blood pressure; cardiovascular risk; population science; pulse pressure

Introduction
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The blood pressure wave consists of a steady and pulsatile component, mean arterial
pressure and pulse pressure, respectively.1 Mean arterial pressure, the product of cardiac
output with peripheral arterial resistance is the force driving blood flow.1 Pulse pressure, the
difference between systolic and diastolic blood pressure, depends on left ventricular
ejection, the elasticity of the central arteries, and the timing and intensity of the backward
wave originating at refection sites in the peripheral circulation. Pulse pressure widens in the
elderly, because with advancing age systolic blood pressure continues to rise, whereas the
age-related increase in diastolic blood pressure levels off or even reverses in the fifth decade
of life.2
Under the premise that systolic blood pressure and pulse pressure reflect arterial stiffness,
the Framingham investigators demonstrated that with increasing age, a gradual shift occurs
from diastolic to systolic pressure and then to pulse pressure as predictors of coronary heart
disease.3 Several other studies showed that pulse pressure, derived from the conventionally
measured blood pressure, predicts adverse outcomes in patients with cardiovascular4 or
renal disease5,6 as well as in populations.7–11 Compared to the conventionally measured
blood pressure, ambulatory monitoring substantially refines risk stratification, but the five
studies that examined the predictive value of ambulatory pulse pressure only included
hypertensive patient12–16 or patients with end-stage renal disease.5 Although described as a
Hypertension. Author manuscript; available in PMC 2015 February 01.
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priority in 2006,17 to our knowledge, current guidelines for the management of
hypertension18–20 do not propose outcome-driven thresholds for pulse pressure
discriminating normal from abnormal values. We addressed these issues in a subject-level
meta-analysis of 9938 people recruited from 11 populations and enrolled in the International
Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO).

Methods
Study Population

NIH-PA Author Manuscript

Previous publications described the construction of the IDACO database.21 All studies
received ethical approval and qualified for inclusion if they involved a random population
sample, contained baseline information on the ambulatory blood pressure and cardiovascular
risk factors, and follow-up of fatal and nonfatal outcomes. All participants gave informed
written consent. The IDACO database21 included 12 randomly recruited population cohorts
and 12,725 participants, but at time of writing of this report, validated information on
outcome was available in only 11 studies (details and references provided in the online Data
Supplement), leaving 12,148 participants. Of those, we excluded 2210, because they were
younger than 18 years (n=74); or because they had fewer than 10 daytime or 5 nighttime
blood pressure readings (n=2136). Thus, the number of subjects included in the present
analysis totaled 9938.
Blood Pressure Measurement
Methods used for conventional and ambulatory blood pressure measurement are described in
detail in Data Supplement. Conventional blood pressure was the average of 2 consecutive
readings. Hypertension was as a conventional blood pressure of ≥140 mm Hg systolic or
≥90 mm Hg diastolic, or use of antihypertensive drugs. Portable monitors were programmed
to obtain ambulatory blood pressure readings at 30-minute intervals throughout the whole
day, or at intervals ranging from 15 to 30 minutes during daytime and from 15 to 60 minutes
at night. Daytime ranged from 10 AM to 8 PM in Europeans and South Americans and from 8
AM to 6 PM in Asians. The corresponding nighttime intervals ranged midnight to 6 AM and from
10 PM to 4 AM. Pulse pressure was the difference between systolic and diastolic blood pressure
and mean arterial pressure was diastolic blood pressure plus one third of pulse pressure.

NIH-PA Author Manuscript

Other Measurements
We used questionnaires to obtain information on each participant’s medical history and
smoking and drinking habits. We measured serum cholesterol and blood glucose by
automated enzymatic methods. Diabetes was the use of antidiabetic drugs, a fasting blood
glucose concentration of ≥7.0 mmol/L,22 a random blood glucose concentration of ≥11.1
mmol/L,22 a self-reported diagnosis, or diabetes documented in practice or hospital records.
Ascertainment of Events
We ascertained vital status and the incidence of fatal and nonfatal diseases from the
appropriate sources in each country, as described in previous publications21 and in Data
Supplement. Fatal and nonfatal stroke did not include transient ischemic attacks. Coronary
events encompassed death from ischemic heart disease, sudden death, nonfatal myocardial
Hypertension. Author manuscript; available in PMC 2015 February 01.
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infarction, and coronary revascularization. Cardiac events comprised coronary endpoints and
fatal and nonfatal heart failure. The composite cardiovascular endpoint included all
aforementioned endpoints plus cardiovascular mortality. In all outcome analyses, we only
considered the first event within each category.
As in previous IDACO analyses, we considered the composite cardiovascular endpoint as
the main outcome, because it provides the largest number of events. We informed sample
size calculations with the event rate of the composite cardiovascular endpoint in the IDACO
cohort (10.7 per 1000 person-years). We used the one-sample test as implemented in the
PROC POWER procedure of the SAS package. To demonstrate a 10% change in the relative
risk associated with each–10 mm Hg increase in 24–h pulse pressure, approximately 7000
subjects would be needed with the 2-sided α-level set at 0.05 and power at 0.90.
Statistical Analysis

NIH-PA Author Manuscript

For database management and statistical analysis, we used SAS software, version 9.3 (SAS
Institute, Carey, NC). We compared means and proportions using the large-sample z-test,
and χ2 statistic, respectively. After stratification for cohort and sex, we interpolated missing
values of body mass index (n=46) and total serum cholesterol (n=683) from the regression
slope on age. In subjects with unknown drinking (n=813) or smoking habits (n=69), we set
the design variable to the cohort- and sex-specific mean of the codes (0,1). Statistical
significance was a 2-sided P value of ≤0.05.
To relate outcome to pulse pressure, while adjusting for covariables, we applied Cox
regression. The baseline characteristics used for adjustment included: cohort, sex, age
(continuous), mean arterial pressure, heart rate, body mass index (continuous), current
smoking and drinking (0,1), serum cholesterol (continuous), history of cardiovascular
disease (0,1) and diabetes mellitus (0,1), and antihypertensive drug treatment (0,1). For
adjustment, mean arterial pressure and heart rate were derived from the same recordings as
pulse pressure (24–h, daytime, nighttime or conventional measurements).

NIH-PA Author Manuscript

Because of the Framingham results23 and the lower age boundary in several randomized
clinical trials on antihypertensive treatment in the elderly,24 we stratified our analyses by 60
years of age. Exploratory analyses demonstrated that the association of endpoints with 24–h
pulse pressure was not always log linear. To account for this nonlinear association, we
applied the deviation from mean coding25 to compute hazard ratios (HRs) in tenths of the
24–h pulse pressure distribution. This approach expresses the risk in each tenth relative to
the overall risk in the whole study population and allows computing 95% confidence
intervals (CIs) for the hazard ratios in all tenths without definition of an arbitrary reference
group. Hazard ratios relating endpoints to mean arterial pressure expressed the risk
associated with a 1–SD increase in the level. We tested heterogeneity in the hazard ratios
across subgroups by introducing the appropriate interaction term in the Cox model. We
applied the generalized R2 statistic to assess the risks additionally explained by 24–h pulse
pressure over and beyond mean arterial pressure and other covariables.26 To assess whether
collinearity between pulse pressure and mean arterial pressure affected our estimates, we
applied penalized Cox regression as applied in the ridging=relative model option of the
PROC PHREG procedure of the SAS package.
Hypertension. Author manuscript; available in PMC 2015 February 01.
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In an attempt to refine the level of pulse pressure that was associated with significantly
increased risk, we did a stepwise analysis. We calculated hazard ratios for 1–mm Hg
increments in pulse pressure for thresholds ranging from the 10th to the 90th percentile.
These hazard ratios expressed the risk in participants whose pulse pressure exceeded the
cutoff point vs. average risk. We plotted these hazard ratios and their 95% confidence limits
vs. the increasing cutoff points with the goal to determine at which level the lower
confidence limit of the hazard ratios crossed unity.

Results
Characteristics of Participants

NIH-PA Author Manuscript

The whole study population comprised 6623 Europeans (66.6%), 1877 Asians (18.9%) and
1438 South Americans (14.5%). Of the 9938 participants, 4703 were women (47.3%), 4058
(40.8%) had hypertension on conventional blood pressure measurement, and 1946 (19.6%)
were taking blood pressure–lowering drugs. Mean age was 52.7±15.8 years. In the whole
study population, average 24–h blood pressure levels were 123.5±14.0 mm Hg systolic,
73.6±8.3 mm Hg diastolic, 49.9±9.6 mm Hg for pulse pressure, and 90.2±9.5 mm Hg for
mean arterial pressure. At enrolment, 2789 participants (28.1%) were current smokers, and
4759 (47.9%) reported intake of alcohol.
Table 1 shows the characteristics of the participants by age group. The median number of
readings averaged to estimate the 24–h pulse pressure was 50 (5th to 95th percentile
interval, 35–81; range, 21–95) in younger participants and 56 (5th to 95th percentile
interval, 35–82; range, 20–99) in the elderly. Table S1 additionally lists the conventional
blood pressure and the daytime and nighttime blood pressures by age group. All of the
differences between the age groups were significant (P≤0.0012) with the exception of the
proportion of Asians (P=0.057).
Analyses of Younger Participants

NIH-PA Author Manuscript

Incidence of Endpoints—Among 6028 younger participants (<60 years), median followup was 12.1 years (5th to 95th percentile interval, 2.5 to 18.2 years). Over 68,853 personyears, 228 participants died (3.3 per 1000 person-years) and 221 experienced a fatal or
nonfatal cardiovascular complication (3.2 per 1000 person-years). The Data Supplement
provides information on the overall and cause-specific number of fatal and nonfatal events.
Categorical Analysis of 24-H Pulse Pressure—Figure 1 shows the hazard ratios
expressing the risk in each tenth of the distribution of the 24–h ambulatory pulse pressure vs.
average risk. Only in the highest tenth of the pulse pressure distribution (threshold, ≥55.6
mm Hg; mean 60.1 mm Hg), the risk of the composite cardiovascular endpoint was elevated
(HR, 1.58; 95% CI, 1.11 to 2.25; P=0.011) with a similar trend for cardiac endpoints (HR,
1.52; CI, 0.99 to 2.33; P=0.056). Otherwise, the risks across tenths of the pulse pressure
distribution (Figure 1) did not deviate from average (P≥0.058). For stroke, Cox models
across tenths of the pulse pressure distribution did not converge, because of the low number
of events (n=63). The HRs expressing the risk associated with a 1–SD increase in mean
arterial pressure were 1.11 (CI, 0.95 to 1.29; P=0.19) for total mortality, 1.40 (CI, 1.09 to
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1.80; P=0.009) for cardiovascular mortality, 1.37 (CI, 1.19 to 1.59; P<0.0001) for a
composite cardiovascular endpoint, and 1.40 (CI, 1.18 to 1.66; P=0.0001) for a cardiac
event.
Stepwise Analysis of Pulse Pressure—Figure S1 shows the HRs of 24–h pulse
pressure levels that stepwise increased by 1 mm Hg from the 10th to the 90th percentile. For
all endpoints under study, the lower boundary of the confidence interval of the successive
HRs did not cross unity.
Analyses of Older Participants
Incidence of Endpoints—Among 3910 older participants (≥60 years), median follow-up
was 10.7 years (5th to 95th percentile interval, 2.5 to 16.1 years). Over 39,923 person-years,
1160 participants died (29.0 per 1000 person-years) and 940 experienced a fatal or nonfatal
cardiovascular complication (23.5 per 1000 personyears). The Data Supplement lists the
number of fatal and nonfatal events.

NIH-PA Author Manuscript
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Categorical Analysis of 24-H Pulse Pressure—Figure 2 shows the hazard ratios
expressing the risk in each tenth of the distribution of the 24–h ambulatory pulse pressure vs.
average risk. The risk of any death, cardiovascular mortality, a composite cardiovascular
endpoint or a cardiac event was consistently elevated in the top tenth of the pulse pressure
distribution (threshold, ≥68.8 mm Hg; mean 76.1 mm Hg). The HRs were 1.30 (CI, 1.09 to
1.55; P=0.004), 1.62 (CI, 1.26 to 2.10; P=0.0002), 1.52 (CI, 1.26 to 1.83; P<0.0001), and
1.69 (CI, 1.33 to 2.15; P<0.0001), respectively. The HR for stroke in the top tenth of the
pulse pressure distribution was 1.40 (CI, 1.04 to 1.89; P=0.028; Figure S2). For
cardiovascular mortality and the composite cardiovascular endpoint, the HRs were 0.66 (CI,
0.45 to 0.97; P=0.033) and 0.78 (CI, 0.61 to 0.99; P=0.040) in the second and third tenth of
the pulse pressure distribution, respectively (Figure 2). Otherwise, the risks across tenths of
the pulse pressure distribution (Figure 2 and Figure S2) did not deviate from average
(P>0.05). The HRs expressing the risk associated with a 1–SD increase in mean arterial
pressure were 1.04 (CI, 0.96 to 1.12; P=0.31) for total mortality, 1.15 (CI, 1.02 to 1.29;
P=0.02) for cardiovascular mortality, 1.19 (CI, 1.10 to 1.29; P<0.0001) for a composite
cardiovascular endpoint, 1.07 (CI, 0.96 to 1.19; P=0.22) for a cardiac event, and 1.39 (CI,
1.23 to 1.58; P<0.0001) for stroke. The R2 statistic for adding a design variable coding for
the top tenth of the 24–h pulse pressure distribution to Cox models including all other
covariables were 0.10% and 0.12% for total and cardiovascular mortality, 0.27%, 0.21%,
0.09% for the composite cardiovascular endpoint, all cardiac events and stroke, respectively.
Stepwise Analysis of Pulse Pressure—Figure 3 shows the hazard ratios for 24–h
pulse pressure levels increasing by 1–mm Hg steps from the 10th up to the 90th percentile in
older participants. For most endpoints under study (Figure 3) with the exception of stroke
(Figure S2), the lower boundary of the confidence interval of the successive HRs crossed the
reference line at levels ranging from 64 mm Hg (composite cardiovascular endpoint) to 69
mm Hg (total mortality and cardiac events).

Hypertension. Author manuscript; available in PMC 2015 February 01.
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Sensitivity Analyses—Excluding one cohort at a time produced confirmatory results as
shown for cardiovascular mortality and the composite cardiovascular endpoint in the Data
Supplement (Table S2). Similarly, when we stratified our analyses in older participants for
ethnicity, sex, presence vs. absence of conventional hypertension, or use vs. nonuse of
antihypertensive drugs, the results remained consistent (0.16≤P≤0.75 for interaction
between subgroups, Table S3). After excluding 863 older participants with a history of
cardiovascular disease or diabetes mellitus, the significance of these interaction terms did
not materially change (0.37≤P≤0.97). Modeling cohort as a random effect in the Cox model
instead of adjusting the model for cohort (Figures S3 and S4), applying ridge regression
(Table S4) or adjusting for systolic or diastolic blood pressure instead of mean arterial
pressure (Table S5) produced consistent results. Finally, when we substituted 24–h pulse
pressure by daytime, nighttime or the conventionally measured pulse pressure, the results
did not change (Figure 4).
Analyses of Younger and Older Participants Combined

NIH-PA Author Manuscript

We tested the interaction between 24–h pulse pressure and age modeled as a categorical or
continuous variable in 9938 participants. In the categorical analyses (Table S6), using as age
cutoff limits 50, 55 or 60 years, none of the interaction terms reached significance
(0.14≤P≤0.72) except for cardiovascular events with 50 years as age cut-off (P=0.005). In
the continuous analyses, The hazard ratios associated with 10–mm Hg higher 24–h pulse
pressure in younger and older participants (<60 vs. ≥60 years) were 1.12 (CI, 0.91–1.38) vs.
1.08 (1.00–1.15) for total mortality (P-value for difference, 0.085), 1.24 (0.86–1.81) vs. 1.13
(1.01–1.25) for cardiovascular mortality (P= 0.020), 1.28 (1.05–1.57) vs. 1.13 (1.05–1.21)
for the composite cardiovascular endpoint (P= 0.009), and 1.21 (CI, 0.96–1.53) vs. 1.17
(1.06–1.28) for cardiac events (P= 0.22).

Discussion

NIH-PA Author Manuscript

After more than 2 decades of research7 pulse pressure remains an elusive cardiovascular risk
factor with findings being inconsistent across studies. Indeed, previous cohort studies found
that peripheral pulse pressure, as measured by conventional sphygmomanometry, was an
independent risk factor in populations,3,7–11 or in patients with hypertension,4,27–29 coronary
heart disease4 or severe renal dysfunction.5,6 Other population studies failed to confirm the
risk associated with pulse pressure30,31 or reported that it was present only in women7 or in
diabetic10 or treated hypertensive patients.29 In addition to the conventional method of blood
pressure measurement, the aforementioned studies had limitations, because they recorded
only fatal endpoints,5–8,10,11,30,31 or applied recruitment criteria confined to high-risk
patients,4,6,27–29,31 a narrow age range7,8 or elderly.11,28 To address these drawbacks, we
applied ambulatory blood pressure monitoring, the current state-of-the-art for blood pressure
measurement,32 and we recorded both fatal and nonfatal endpoints in randomly recruited
populations with age ranging from 18 to 93 years. The key finding of our study was that 24–
h pulse pressure did not substantially add to risk stratification below age 60; in the elderly,
24–h pulse pressure was a weak risk factor with levels below 64 mm Hg probably being
innocuous. For all endpoints under study, 24–h pulse pressure remained a significant
predictor of outcome with either 24–h mean arterial pressure or 24–diastolic blood pressure
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as covariable in the Cox models, but it lost significance for all-cause mortality and stroke
with 24–h systolic blood pressure in the model. These findings suggest that systolic blood
pressure might be the major blood pressure component driving the risk associated with pulse
pressure. Using continuous analyses in our current study, the hazard ratios expressing the
risk associated with 10–mm Hg wider 24–h pulse pressure, where higher in younger than
older participants for the composite cardiovascular endpoint (1.28 vs. 1.13). However, these
hazard ratios only reflect relative risk. The composite cardiovascular endpoint was running
at rates of 3.2 and 23.5 events per 1000 person-year in younger and older participants,
respectively. In terms of absolute risk, 24–h pulse pressure therefore was a more important
predictor in older than younger participants.

NIH-PA Author Manuscript

Already in 1971, the Framingham investigators33 demonstrated that the role of diastolic and
systolic blood pressure as risk indicators depend on age. In 2001, they reported that with
increasing age, there was a gradual shift from diastolic blood pressure to systolic blood
pressure and then to pulse pressure as predictors of coronary heart disease.3 In 1989, the
Multiple Risk Factor Trial researchers demonstrated that both systolic and diastolic blood
pressure determine cardiovascular risk.34 Also in 1989, Darne and coworkers, by applying
principal component analysis, established a steady and pulsatile component of blood
pressure, which were unrelated to one another, but strongly correlated with mean arterial
pressure and pulse pressure, respectively.7 Guided by these seminal publications,3,7,33,34 we
stratified our main analyses by age (<60 vs. ≥60 years) and we modeled pulse pressure as
risk factor, while accounting for mean arterial pressure.

NIH-PA Author Manuscript

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure18 proposed that pulse pressure is only marginally
stronger than systolic blood pressure for risk stratification in individuals over age 60, and
that under age 60, pulse pressure is not predictive. According to the 2007 European
guideline19 pulse pressure is a derived measure, which combines the imprecision of the
original systolic and diastolic measurements. The 2007 guideline stated that, although levels
of 50 to 55 mm Hg have been suggested,17 no practical cutoff values separating pulse
pressure normality from abnormality is available. The 2013 European guideline increased
this threshold to 60 mm Hg without any justification.20 Our current analyses established that
below age 60, a 24–h pulse pressure level around 60 mm Hg might be associated with
increased risk, but that a safe threshold could not be established. Among the elderly, a 24–h
pulse pressure of around 76 mm Hg was definitely associated with higher risk and levels
below 64 were probably safe. Using intra-arterial monitoring, Khattar and colleagues
observed that survival rates were highest below age 60, if the 24–h pulse pressure was less
than 70 and highest among elderly with a 24–h pulse pressure of 70 mm Hg or more.14 To
our knowledge, Khattar’s report14 is the only other study proposing an outcome-driven
threshold for 24–h pulse pressure. However, this article does not include any justification
why 70–mm Hg was chosen as threshold in a dichotomized analysis. The results rested on
an unadjusted Kaplan-Meier survival function analysis, and the study population consisted
of patients with essential hypertension, in whom treatment had been withdrawn for 8
weeks.14 To our knowledge, all other proposals for pulse pressure thresholds relied on
conventional blood pressure measurement. In analyses adjusted but not stratified for age, 2
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studies9,27 derived a threshold from the 66th percentile of the pulse pressure distribution.
Madhavan proposed 63 mm Hg based on the incidence of myocardial infarction in 2207
hypertensive patients aged 55 years,27 and Borghi suggested 67 mm Hg based on the
incidence of cardiovascular disease among 2939 Italian people (14 to 84 years). Asmar
derived a threshold of 65 mm Hg from the mean pulse pressure plus 2 SDs in 61,724 French
people (16 to 90 years).35

NIH-PA Author Manuscript

Our current results must be interpreted within the context of some limitations. First, because
of the low event rates below middle age, our analyses did not answer the issue whether pulse
pressure has a different prognostic impact in young compared with older people. However,
as reviewed elsewhere,36 our current study along with the Framingham report3 is one of the
few with long-term follow-up of subjects younger than 40 years. Second, we did not account
for regression dilution bias.30 However, we previously demonstrated that such correction is
not necessary for blood pressure indexes obtained by 24–h ambulatory monitoring.37 Third,
we had no information on central pulse pressure. As demonstrated in Europeans38 and
Chinese,39 with advancing age, systolic augmentation increases and pressure amplification,
the difference between peripheral and central systolic blood pressure, decreases. By
measuring pulse pressure at a peripheral site, we might have underestimated its prognostic
significance, in particular in younger people. Finally, oscillometric and auscultatory
estimates of pulse pressure might differ. However, our findings were consistent regardless of
the interval over which the ambulatory blood pressure was measured and on ambulatory
(oscillometric) and conventional (predominantly auscultatory) measurement.
Perspectives
Based on our observations in randomly recruited people, pulse pressure adds little
information on cardiovascular outcomes below age 60. In the elderly, ambulatory pulse
pressure is a risk factor with levels below 64 mm Hg probably being harmless. However,
using this threshold in clinical practice might be of little value, because ambulatory pulse
pressure does not substantially enhance risk stratification over and beyond the steady
component of the blood pressure level and other cardiovascular risk factors. We suggest that
the threshold proposed for pulse pressure in the European 2013 guideline,20 irrespective of
measurement technique, might be revised from the perspective of our current findings.
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What is new?
This is the first population-based study to derive outcome-driven threshold for 24–h pulse
pressure.
What is relevant?
▫

24–H pulse pressure does not substantially add to risk stratification below
age 60.

▫

Starting from 60 years onwards, 24–h pulse pressure levels of 70 mm Hg or
higher carry an increased cardiovascular risk, whereas levels below 64 mm
Hg are probably innocuous. However, while accounting for all covariables,
having a 24–h pulse pressure in the top tenth of the distribution contributed
less than 0.3% to the overall risk among elderly.

▫

Findings for daytime, nighttime and conventional pulse pressure were similar
to those for 24–ambulatory pulse pressure.
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Summary
The present report is the first to provide outcome-driven thresholds for pulse pressure on
24–h ambulatory measurement. These findings could inform guidelines and be of help to
clinicians in diagnosing and managing patients.
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Figure 1. Hazard ratios in tenths of the distribution of 24–h pulse pressure in 6028 younger participants

Hazard ratios for total (A) and cardiovascular (B) mortality and for cardiovascular (C) and cardiac (D) events express the risk in
each tenth compared with average risk. Hazard ratios were adjusted for cohort, sex, age, 24–h mean arterial pressure, 24–h heart
rate, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular disease and diabetes, antihypertensive
drug treatment. Vertical bars denote 95% confidence intervals. For each tenth, the number of events and unadjusted incidence
rates (in percent) are given. The P value refers to the significance of the hazard ratio in the top tenth of the 24–h pulse pressure
distribution.
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Figure 2. Hazard ratios in tenths of the distribution of 24–h pulse pressure in 3910 older participants

Hazard ratios for total (A) and cardiovascular (B) mortality and for cardiovascular (C) and cardiac (D) events express the risk in
each tenth compared with average risk. The hazard ratios were adjusted as in Figure 1. Vertical bars denote 95% confidence
intervals. For each tenth, the number of events and unadjusted incidence rates (in percent) are given. The P value refers to the
significance of the hazard ratio in the top tenth of the 24–h pulse pressure distribution.
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Figure 3. Hazard ratios according to 24–h pulse pressure levels ranging from the 10th to the 90th percentile in 3910 older participants

Hazard ratios for total mortality (A) and cardiovascular (B) mortality and for cardiovascular (C) and cardiac (D) events express
the risk at each level of pulse pressure compared with average risk. Solid and dotted lined denote the point estimates and the
95% confidence intervals, respectively. The hazard ratios were adjusted as in Figure 1.
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Figure 4. Multivariable-adjusted hazard ratios for outcomes in relation to 24–h (A), daytime (B), nighttime (C), and conventional (D)
pulse pressure in 3910 older participants
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The hazard ratios, presented with 95% confidence interval (CI), express the risk in the top tenth compared with the average risk
in the participants. Pulse pressure thresholds delineating the top tenth were ≥68.8, ≥71.3, ≥66.8, and ≥80.0 mm Hg for 24–h,
daytime, nighttime and conventional blood pressure measurement; the corresponding mean levels of pulse pressure in the top
tenth were 76.1, 78.8, 75.6 and 89.0 mm Hg, respectively. All models were adjusted for cohort, sex, age, mean arterial pressure
and heart rate (on 24–h, daytime, nighttime, conventional measurement in panels A, B, C, and D, respectively), body mass
index, smoking and drinking, serum cholesterol, history of cardiovascular disease and diabetes, and antihypertensive drug
treatment. P values are for the risk in the top tenth relative to the overall risk in the whole study population. CV denotes
cardiovascular. E/R1–9 and E/R10 indicate the number of events and participants at risk below the 90th percentile of the pulse
pressure distribution and in the top tenth, respectively.
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Baseline Characteristics of Participants by Age Group
Characteristic

<60 years
(N=6028)

≥60 years
(N=3910)

953 (15.8)

924 (23.6)

European

4061 (67.4)

2562 (65.5)

South American

1014 (16.8)

424 (10.8)

3239 (53.7)

1464 (37.4)

Ethnicity
Asian

Women
Cardiovascular risk factors
Smoking

1857 (30.9)

932 (24.1)

Drinking alcohol

2795 (47.7)

1964 (60.1)
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Diabetes mellitus

247 (4.1)

411 (10.5)

Cardiovascular disease

269 (4.5)

521 (13.3)

Hypertension

1529 (25.4)

2529 (64.7)

Antihypertensive drug treatment

619 (10.3)

1327 (34.1)

Age, years

42.5±11.1

68.6±5.6

Body mass index, kg/m2

25.1±4.3

25.7±4.0

Serum total cholesterol, mmol/L

5.45±1.14

5.83±1.15

Blood glucose, mmol/L

5.01±1.14

5.52±1.60

Systolic blood pressure, mm Hg

119.4±12.0

129.8±14.5

Diastolic blood pressure, mm Hg

73.0±8.3

74.6±8.3

Pulse pressure, mm Hg

46.4±7.2

55.2±10.5

24-h blood pressure measurements

Mean arterial pressure, mm Hg

88.5±9.1

93.0±9.6

Heart rate, beats per minute

73.6±8.9

69.9±9.1

Data are No. (%) or mean±SD. Hypertension is a conventional blood pressure of ≥140 mm Hg systolic or ≥90 mm Hg diastolic or use of
antihypertensive drugs. To convert glucose and cholesterol from mmol/l to mg/dl, multiply by 18.01 and 38.61, respectively. All of the differences
between age groups were significant (P<0.0001) with the exception of the proportion of Asians (P=0.057).
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